- Home
- HPAI vs CVRX Comparison
HPAI vs CVRX Comparison
Compare HPAI & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPAI
- CVRX
- Stock Information
- Founded
- HPAI 2023
- CVRX 2000
- Country
- HPAI Singapore
- CVRX United States
- Employees
- HPAI N/A
- CVRX N/A
- Industry
- HPAI
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- HPAI
- CVRX Health Care
- Exchange
- HPAI NYSE
- CVRX Nasdaq
- Market Cap
- HPAI 189.4M
- CVRX 188.9M
- IPO Year
- HPAI N/A
- CVRX 2021
- Fundamental
- Price
- HPAI $4.85
- CVRX $8.53
- Analyst Decision
- HPAI
- CVRX Buy
- Analyst Count
- HPAI 0
- CVRX 7
- Target Price
- HPAI N/A
- CVRX $13.67
- AVG Volume (30 Days)
- HPAI 18.6K
- CVRX 196.8K
- Earning Date
- HPAI 11-12-2024
- CVRX 10-24-2024
- Dividend Yield
- HPAI N/A
- CVRX N/A
- EPS Growth
- HPAI N/A
- CVRX N/A
- EPS
- HPAI N/A
- CVRX N/A
- Revenue
- HPAI $21,307,683.00
- CVRX $44,393,000.00
- Revenue This Year
- HPAI N/A
- CVRX $31.01
- Revenue Next Year
- HPAI N/A
- CVRX $30.66
- P/E Ratio
- HPAI $26.56
- CVRX N/A
- Revenue Growth
- HPAI 377.09
- CVRX 43.94
- 52 Week Low
- HPAI $3.07
- CVRX $6.40
- 52 Week High
- HPAI $14.74
- CVRX $33.14
- Technical
- Relative Strength Index (RSI)
- HPAI N/A
- CVRX 47.33
- Support Level
- HPAI N/A
- CVRX $8.43
- Resistance Level
- HPAI N/A
- CVRX $8.96
- Average True Range (ATR)
- HPAI 0.00
- CVRX 0.52
- MACD
- HPAI 0.00
- CVRX 0.01
- Stochastic Oscillator
- HPAI 0.00
- CVRX 45.29
About HPAI HELPORT AI LTD
Helport AI Ltd is a AI technology company based in Singapore dedicated to serving enterprises' customer contact centers with intelligent products, solutions, and a digital platform. Its software, Helport AI Assist (AI Assist), provides tailored AI-powered guidance and oversight for contact center interactions and customer experience, with functions including Agent Assistant, Quality Assurance (QA) Assistant, Supervisor Assistant, and Knowledge Base Assistant.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.